NEW YORK--(BUSINESS WIRE)--Vivaldi Biosciences Inc., a biotechnology company focused on the development of vaccines for influenza, today announced the appointment of William (Bill) H. Wainwright, PhD as Vice President, Vaccine Development. In this newly created position, Dr. Wainwright has responsibility for the development of Vivaldi’s live attenuated vaccine candidates for seasonal and pandemic influenza, from pre-clinical evaluation through Phase I/II clinical trials. His responsibilities include development of manufacturing processes and quality control procedures, and manufacture of clinical trial material in compliance with global quality standards.
